Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.

ABSTRACT: Recent early stage clinical trials evaluating the adoptive transfer of patient CD8(+) T-cells re-directed with antigen receptors recognizing tumors have shown very encouraging results. These reports provide strong support for further development of the therapeutic concept as a curative cancer treatment. In this respect combining the adoptive transfer of tumor-specific T-cells with therapies that increase their anti-tumor capacity is viewed as a promising strategy to improve treatment outcome. The ex vivo genetic engineering step that underlies T-cell re-direction offers a unique angle to combine antigen receptor delivery with the targeting of cell-intrinsic pathways that restrict T-cell effector functions. Recent progress in genome editing technologies such as protein- and RNA-guided endon

SUBMITTER: Lloyd A 

PROVIDER: S-EPMC3733021 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature